Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Andrew Dudum cofounded online pharmacy Hims & Hers eight years ago, when he was 27 years old. He’s now the latest to make a ...

The celebrated actress has lost more than 100Ib after turning to controversial diabetes jab Ozempic - now better known for its impact on tackling obesity ...

Novo Nordisk A/S (NYSE: NVO) is seeking FDA approval for the pill version of its obesity drug, Wegovy. The company highlights ...

Novo Nordisk, which also makes Wegovy, fell victim to 'compounding' - a practice in the US that allows pharmacies to produce ...

Bio-Techne surpasses profit expectations with significant growth in its research products, leading to the announcement of a ...

Novo Nordisk stock jumped early Wednesday despite cutting its 2025 outlook due to what Novo says is illegal compounding of ...

A post-earnings rally in Hims & Hers Health Inc. has turned co-founder and Chief Executive Officer Andrew Dudum into a weight-loss billionaire.

Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is ...

Investors are betting that Lilly will maintain its momentum. Its share price has climbed by a third since the start of 2024; ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Wegovy and Ozempic are both semaglutide weight loss medications, but they’re prescribed differently based on who qualifies.